Policy / Pricing US launches probe of German ‘underpayment’ for medicines PharmaphorumA Section 301 probe by the US Trade Representative into Germany's medicine pricing and reimbursement policies raises the threat of punitive tariffs.Read full story pharminent June 19, 2026 (Last updated: June 22, 2026) Pharmaphorum A Section 301 probe by the US Trade Representative into Germany’s medicine pricing and reimbursement policies raises the threat of punitive tariffs. Read full story Post navigation Previous: Biogen to acquire RayThera for up to $1bnNext: Denali sells FDA voucher for $195M to support neurodegenerative pipeline Related Stories Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026 Policy / Pricing Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain pharminent August 13, 2026 Policy / Pricing Trump signs order that nearly halves childhood immunisation coverage pharminent August 11, 2026
